The University of Southampton
University of Southampton Institutional Repository

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral blood (PB) and display major shifts in Bcl-2 family members between those compartments. Specifically, Bcl-XL and Mcl-1, which are not targeted by the Bcl-2 inhibitor venetoclax, are increased in the LN. Because ibrutinib forces CLL cells out of the LN, we hypothesized that ibrutinib may thereby affect expression of Bcl-XL and Mcl-1 and sensitize CLL cells to venetoclax. We investigated expression of Bcl-2 family members in patients under ibrutinib or venetoclax treatment, combined with dissecting functional interactions of Bcl-2 family members, in an in vitro model of venetoclax resistance. In the PB, recent LN emigrants had higher Bcl-XL and Mcl-1 expression than did cells immigrating back to the LN. Under ibrutinib treatment, this distinction collapsed; significantly, the pretreatment profile reappeared in patients who relapsed on ibrutinib. However, in response to venetoclax, Bcl-2 members displayed an early increase, underlining the different modes of action of these 2 drugs. Profiling by BH3 mimetics was performed in CLL cells fully resistant to venetoclax due to CD40-mediated induction of Bcl-XL, Mcl-1, and Bfl-1. Several dual or triple combinations of BH3 mimetics were highly synergistic in restoring killing of CLL cells. Lastly, we demonstrated that proapoptotic Bim interacts with antiapoptotic Bcl-2 members in a sequential manner: Bcl-2 > Bcl-XL > Mcl-1 > Bfl-1. Combined, the data indicate that Bcl-XL is more important in venetoclax resistance than is Mcl-1 and provide biological rationale for potential synergy between ibrutinib and venetoclax.

0006-4971
2918-2926
Haselager, Marco Vincent
29ea9d3b-c1fe-45b9-8998-4b7b5e202145
Kielbassa, Karoline
88256acf-629a-4865-8a02-442d7dfd9983
Ter Burg, Johanna
7929d2e6-01e2-4ebb-9b96-a8a7c53266c2
Bax, Danique Johanna Cornelia
c203f894-7ea0-4ea4-838d-e376699655d7
Fernandes, Stacey Marie
6f52ea27-6217-402a-8a9d-f7b22742a069
Borst, Jannie
441e3d1f-8d6b-428e-b82e-ad856ffe9e1c
Tam, Constantine
29399e89-1999-4a9d-af9d-61f5abd86fba
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Chiodin, Giorgia
4b3e9525-b377-4d16-b69a-e05d2e7854fe
Brown, Jennifer R.
d45373cf-f656-4c6b-9397-3afffa4e1010
Dubois, Julie
e02d07c5-3bc5-445f-b906-23b3044652f3
Kater, Arnon P.
b0c9bb11-e6e5-4c8f-be47-a0b63aca2073
Eldering, Eric
3ceb48b0-8d2c-47b6-b8a0-0aff486e2e0f
Haselager, Marco Vincent
29ea9d3b-c1fe-45b9-8998-4b7b5e202145
Kielbassa, Karoline
88256acf-629a-4865-8a02-442d7dfd9983
Ter Burg, Johanna
7929d2e6-01e2-4ebb-9b96-a8a7c53266c2
Bax, Danique Johanna Cornelia
c203f894-7ea0-4ea4-838d-e376699655d7
Fernandes, Stacey Marie
6f52ea27-6217-402a-8a9d-f7b22742a069
Borst, Jannie
441e3d1f-8d6b-428e-b82e-ad856ffe9e1c
Tam, Constantine
29399e89-1999-4a9d-af9d-61f5abd86fba
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Chiodin, Giorgia
4b3e9525-b377-4d16-b69a-e05d2e7854fe
Brown, Jennifer R.
d45373cf-f656-4c6b-9397-3afffa4e1010
Dubois, Julie
e02d07c5-3bc5-445f-b906-23b3044652f3
Kater, Arnon P.
b0c9bb11-e6e5-4c8f-be47-a0b63aca2073
Eldering, Eric
3ceb48b0-8d2c-47b6-b8a0-0aff486e2e0f

Haselager, Marco Vincent, Kielbassa, Karoline, Ter Burg, Johanna, Bax, Danique Johanna Cornelia, Fernandes, Stacey Marie, Borst, Jannie, Tam, Constantine, Forconi, Francesco, Chiodin, Giorgia, Brown, Jennifer R., Dubois, Julie, Kater, Arnon P. and Eldering, Eric (2020) Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood, 136 (25), 2918-2926. (doi:10.1182/blood.2019004326).

Record type: Article

Abstract

Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral blood (PB) and display major shifts in Bcl-2 family members between those compartments. Specifically, Bcl-XL and Mcl-1, which are not targeted by the Bcl-2 inhibitor venetoclax, are increased in the LN. Because ibrutinib forces CLL cells out of the LN, we hypothesized that ibrutinib may thereby affect expression of Bcl-XL and Mcl-1 and sensitize CLL cells to venetoclax. We investigated expression of Bcl-2 family members in patients under ibrutinib or venetoclax treatment, combined with dissecting functional interactions of Bcl-2 family members, in an in vitro model of venetoclax resistance. In the PB, recent LN emigrants had higher Bcl-XL and Mcl-1 expression than did cells immigrating back to the LN. Under ibrutinib treatment, this distinction collapsed; significantly, the pretreatment profile reappeared in patients who relapsed on ibrutinib. However, in response to venetoclax, Bcl-2 members displayed an early increase, underlining the different modes of action of these 2 drugs. Profiling by BH3 mimetics was performed in CLL cells fully resistant to venetoclax due to CD40-mediated induction of Bcl-XL, Mcl-1, and Bfl-1. Several dual or triple combinations of BH3 mimetics were highly synergistic in restoring killing of CLL cells. Lastly, we demonstrated that proapoptotic Bim interacts with antiapoptotic Bcl-2 members in a sequential manner: Bcl-2 > Bcl-XL > Mcl-1 > Bfl-1. Combined, the data indicate that Bcl-XL is more important in venetoclax resistance than is Mcl-1 and provide biological rationale for potential synergy between ibrutinib and venetoclax.

Text
Haselager_Blood_R2 - Accepted Manuscript
Download (1MB)

More information

Accepted/In Press date: 17 June 2020
e-pub ahead of print date: 30 June 2020
Published date: 17 December 2020

Identifiers

Local EPrints ID: 444114
URI: http://eprints.soton.ac.uk/id/eprint/444114
ISSN: 0006-4971
PURE UUID: 28a850b6-c786-4ed0-a672-ad09f0e34048
ORCID for Francesco Forconi: ORCID iD orcid.org/0000-0002-2211-1831

Catalogue record

Date deposited: 25 Sep 2020 16:36
Last modified: 17 Mar 2024 05:46

Export record

Altmetrics

Contributors

Author: Marco Vincent Haselager
Author: Karoline Kielbassa
Author: Johanna Ter Burg
Author: Danique Johanna Cornelia Bax
Author: Stacey Marie Fernandes
Author: Jannie Borst
Author: Constantine Tam
Author: Giorgia Chiodin
Author: Jennifer R. Brown
Author: Julie Dubois
Author: Arnon P. Kater
Author: Eric Eldering

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×